MX2018005625A - Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales. - Google Patents
Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales.Info
- Publication number
- MX2018005625A MX2018005625A MX2018005625A MX2018005625A MX2018005625A MX 2018005625 A MX2018005625 A MX 2018005625A MX 2018005625 A MX2018005625 A MX 2018005625A MX 2018005625 A MX2018005625 A MX 2018005625A MX 2018005625 A MX2018005625 A MX 2018005625A
- Authority
- MX
- Mexico
- Prior art keywords
- cranial nerves
- treating disease
- anesthesia
- auricular anesthesia
- auricular
- Prior art date
Links
- 206010002091 Anaesthesia Diseases 0.000 title abstract 2
- 230000037005 anaesthesia Effects 0.000 title abstract 2
- 210000003792 cranial nerve Anatomy 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 210000000613 ear canal Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Métodos para tratar una variedad de enfermedades que comprende emplear anestesia auricular de varios nervios craneales. Se administra una composición farmacéutica en un canal auditivo de un sujeto que necesita de tal tratamiento, la composición incluye un analgésico y/o al menos un anestésico. También se proporcionan las composiciones útiles en los métodos enseñados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819023P | 2013-05-03 | 2013-05-03 | |
| US14/931,581 US9968589B2 (en) | 2013-05-03 | 2015-11-03 | Method of treating disease by auricular anesthesia of cranial nerves |
| PCT/US2016/060085 WO2017079270A1 (en) | 2013-05-03 | 2016-11-02 | Method of treating disease by auricular anesthesia of cranial nerves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005625A true MX2018005625A (es) | 2018-12-06 |
| MX390998B MX390998B (es) | 2025-03-21 |
Family
ID=51844020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015194A MX381106B (es) | 2013-05-03 | 2014-05-05 | Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales. |
| MX2018005625A MX390998B (es) | 2013-05-03 | 2016-11-02 | Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015194A MX381106B (es) | 2013-05-03 | 2014-05-05 | Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20140357686A1 (es) |
| EP (2) | EP2991620B1 (es) |
| JP (3) | JP6433985B2 (es) |
| KR (2) | KR102086709B1 (es) |
| CN (2) | CN105163718B (es) |
| AU (2) | AU2014262148B2 (es) |
| CA (2) | CA2910422C (es) |
| DK (1) | DK2991620T3 (es) |
| ES (1) | ES2823624T3 (es) |
| HK (1) | HK1212230A1 (es) |
| IL (2) | IL242339B (es) |
| MX (2) | MX381106B (es) |
| MY (2) | MY180310A (es) |
| RU (2) | RU2687249C2 (es) |
| SG (1) | SG11201508509XA (es) |
| WO (2) | WO2014179814A1 (es) |
| ZA (2) | ZA201508782B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2991620B1 (en) * | 2013-05-03 | 2020-07-08 | Crews, Thomas, M. | Combinations of antipyrine and benzocaine for the treatment of diseases associated with a cranial nerve |
| WO2016137352A1 (ru) * | 2015-02-26 | 2016-09-01 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией |
| EP3509585B1 (en) | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| US20220105052A1 (en) * | 2016-12-26 | 2022-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| CN107789621A (zh) * | 2017-12-15 | 2018-03-13 | 阜阳市平衡医疗保健器械有限公司 | 一种治疗头痛的药物及其配制方法 |
| US11607275B2 (en) * | 2019-05-20 | 2023-03-21 | Medtronic Ireland Manufacturing Unlimited Company | Selection of hypertensive patients for treatment with renal denervation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19524691A1 (de) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
| RU2104056C1 (ru) * | 1995-07-10 | 1998-02-10 | Александр Александрович Ланцов | Способ лечения периферических поражений лицевого нерва |
| JPH1094613A (ja) * | 1996-08-02 | 1998-04-14 | Mieko Sato | 食欲調整用具 |
| US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
| AU5170400A (en) * | 1999-05-27 | 2000-12-18 | George F. El Khoury | Topical application of muscarinic and opioid agents for treatment of tinnitus |
| DE10322497A1 (de) * | 2003-05-19 | 2004-12-09 | Liedtke, Rainer K., Dr. | Topisch pharmakologische Vorbeugung und Therapie der Hyperakusis |
| US8940321B2 (en) * | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| US8755892B2 (en) * | 2007-05-16 | 2014-06-17 | Cardiac Pacemakers, Inc. | Systems for stimulating neural targets |
| WO2011019954A2 (en) * | 2009-08-13 | 2011-02-17 | Yehuda Ivri | Intracochlear drug delivery to the central nervous system |
| WO2011028915A2 (en) * | 2009-09-03 | 2011-03-10 | University Of Chicago | Platelet aggregation inhibitors |
| US9687387B2 (en) * | 2011-03-11 | 2017-06-27 | Yoseph Yaacobi | System and methods for treating ear disorders |
| EP2991620B1 (en) * | 2013-05-03 | 2020-07-08 | Crews, Thomas, M. | Combinations of antipyrine and benzocaine for the treatment of diseases associated with a cranial nerve |
-
2014
- 2014-05-05 EP EP14791131.7A patent/EP2991620B1/en active Active
- 2014-05-05 RU RU2015148757A patent/RU2687249C2/ru active
- 2014-05-05 ES ES14791131T patent/ES2823624T3/es active Active
- 2014-05-05 CN CN201480024269.1A patent/CN105163718B/zh active Active
- 2014-05-05 DK DK14791131.7T patent/DK2991620T3/da active
- 2014-05-05 AU AU2014262148A patent/AU2014262148B2/en active Active
- 2014-05-05 WO PCT/US2014/036855 patent/WO2014179814A1/en not_active Ceased
- 2014-05-05 SG SG11201508509XA patent/SG11201508509XA/en unknown
- 2014-05-05 CA CA2910422A patent/CA2910422C/en active Active
- 2014-05-05 US US14/270,238 patent/US20140357686A1/en not_active Abandoned
- 2014-05-05 JP JP2016512111A patent/JP6433985B2/ja active Active
- 2014-05-05 KR KR1020157033239A patent/KR102086709B1/ko active Active
- 2014-05-05 HK HK16100269.6A patent/HK1212230A1/xx unknown
- 2014-05-05 MY MYPI2015002669A patent/MY180310A/en unknown
- 2014-05-05 MX MX2015015194A patent/MX381106B/es unknown
-
2015
- 2015-10-29 IL IL242339A patent/IL242339B/en active IP Right Grant
- 2015-11-03 US US14/931,581 patent/US9968589B2/en active Active
- 2015-12-01 ZA ZA2015/08782A patent/ZA201508782B/en unknown
-
2016
- 2016-11-02 AU AU2016349784A patent/AU2016349784B2/en active Active
- 2016-11-02 RU RU2018118068A patent/RU2701548C1/ru active
- 2016-11-02 MX MX2018005625A patent/MX390998B/es unknown
- 2016-11-02 EP EP16862858.4A patent/EP3370716A4/en active Pending
- 2016-11-02 MY MYPI2018701738A patent/MY196979A/en unknown
- 2016-11-02 JP JP2018543020A patent/JP2018536709A/ja active Pending
- 2016-11-02 CA CA3004160A patent/CA3004160C/en active Active
- 2016-11-02 CN CN201680077107.3A patent/CN108430470A/zh active Pending
- 2016-11-02 KR KR1020187015606A patent/KR102796310B1/ko active Active
- 2016-11-02 WO PCT/US2016/060085 patent/WO2017079270A1/en not_active Ceased
-
2018
- 2018-04-29 IL IL259019A patent/IL259019B/en active IP Right Grant
- 2018-05-14 US US15/978,742 patent/US11123284B2/en active Active
- 2018-05-25 ZA ZA2018/03483A patent/ZA201803483B/en unknown
-
2021
- 2021-09-20 US US17/479,780 patent/US20220387307A1/en not_active Abandoned
-
2022
- 2022-02-07 JP JP2022016897A patent/JP7512317B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200001A1 (ar) | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم | |
| MX2018005625A (es) | Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales. | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| UA113541C2 (xx) | Заміщені піролідин-2-карбоксаміди | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| PH12015502002B1 (en) | Tripeptide epoxy ketone protease inhibitors | |
| MX368833B (es) | Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor. | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| MX2015009602A (es) | Piridona amidas como moduladores de canales de sodio. | |
| UA124922C2 (uk) | Модулятори ядерного транспорту та їх застосування | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| JO3326B1 (ar) | مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MX381102B (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |